{
    "eid": "2-s2.0-85112070346",
    "title": "Budget Impact of Sequential Treatment with Biologics, Biosimilars, and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Thai Patients with Rheumatoid Arthritis",
    "cover-date": "2021-09-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Antirheumatic agents",
        "Biological pharmaceuticals",
        "Biologics",
        "Biosimilars",
        "Budget",
        "DMARDs",
        "Healthcare costs",
        "Rheumatoid arthritis",
        "Targeted therapy"
    ],
    "authors": [
        "Manathip Osiri",
        "Piyameth Dilokthornsakul",
        "Sasitorn Chokboonpium",
        "Pichaya Suthipinijtham",
        "Ajchara Koolvisoot"
    ],
    "citedby-count": 0,
    "ref-count": 35,
    "ref-list": [
        "Rheumatoid arthritis",
        "Global, regional and national burden of rheumatoid arthritis 1990\u20132017: a systematic analysis of the Global Burden of Disease study 2017",
        "A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective",
        "APLAR rheumatoid arthritis treatment recommendations",
        "2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis",
        "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update",
        "An economic evaluation of tofacitinib treatment in rheumatoid arthritis: modeling the cost of treatment strategies in the United States",
        "Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: analysis from the Thai Rheumatic Disease Prior Authorization registry",
        "Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists",
        "Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis",
        "Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54",
        "Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))",
        "Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study",
        "Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group",
        "Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial",
        "Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study",
        "A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate",
        "Baricitinib in patients with rheumatoid arthritis and an inadequate response to conventional disease-modifying antirheumatic drugs in united states and rest of world: a subset analysis",
        "A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study",
        "Long-term efficacy, safety, and immunogenicity of the infliximab (IFX) biosimilar, PF-06438179/GP1111, in patients with rheumatoid arthritis after switching from reference IFX or continuing biosimilar therapy: week 54\u201378 data from a randomized, double-blind, phase III trial",
        "Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 7 years: an updated integrated safety analysis 2019 ACR/ARP annual meeting",
        "Safety and efficacy of subcutaneous golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: final 5-year results of the GO-FORWARD trial",
        "OP0104-Tocilizumab: dose reduction or interval spacing\u2014which proves a better tapering strategy for rheumatoid arthritis in clinical remission?",
        "Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years",
        "Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity",
        "Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis",
        "Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study",
        "Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study",
        "Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation",
        "Cost-effectiveness of early treatment with originator biologics or their biosimilars after methotrexate failure in patients with established rheumatoid arthritis",
        "Epidemiology of rheumatic disease in rural Thailand: a WHO-ILAR COPCORD study. Community oriented programme for the control of rheumatic disease"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60199575",
            "affilname": "Siriraj Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Pitsanulok",
            "@id": "60022498",
            "affilname": "Naresuan University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022498",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "117739285",
            "affilname": "Pfizer (Thailand) Limited",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/117739285",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Pfizer employee"
    ]
}